Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma

Published:2024-09-12 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Maas Carolien C. H. M.^ORCID,van Klaveren David,Durmaz Müjde^ORCID,Visser Otto,Issa Djamila E.,Posthuma Eduardus F. M.,Zijlstra Josée M.,Chamuleau Martine E. D.^ORCID,Lugtenburg Pieternella J.,Kersten Marie José^ORCID,Dinmohamed Avinash G.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01137-0.pdf

Reference46 articles.

1. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J cancer. 2011;105:1684–92.

3. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. LID, Medical sciences (Basel, Switzerland) - https://doi.org/10.3390/medsci9010005.

4. van de Schans SAM, Issa DE, Visser O, Nooijen P, Huijgens PC, Karim-Kos HE, et al. Diverging trends in incidence and mortality, and improved survival of non-Hodgkin’s lymphoma, in the Netherlands, 1989–2007. Ann Oncol. 2012;23:171–82.

5. Durmaz M, Visser O, Posthuma EFM, Brouwer RE, Issa DE, de Jong D, et al. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. Blood Cancer J. 2022;12:38.